Lack of anti-inflammatory effect of botulinum toxin type A in experimental models of inflammation

Fundamental and Clinical Pharmacology

Volumn 22, Issue 5, 2008, Pages 503-509

  Bach Rojecky, Lidija ^a   Dominis, Mara ^b   Lacković, Zdravko ^c  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b University of Zagreb   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Botulinum toxin; Capsaicin; Carrageenan; Inflammation; Pain

Indexed keywords

BOTULINUM TOXIN A; CAPSAICIN; CARRAGEENAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EXOCYTOSIS; EXPERIMENTAL MODEL; EXTRAVASATION; HISTOPATHOLOGY; INFLAMMATION; MALE; MEDICAL PHOTOGRAPHY; NERVE ENDING; NEUROTRANSMITTER RELEASE; NONHUMAN; PARAMETER; PAW EDEMA; PRIORITY JOURNAL; PROTEIN TRANSPORT; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BOTULINUM TOXIN TYPE A; CAPSAICIN; CARRAGEENAN; DISEASE MODELS, ANIMAL; EDEMA; INFLAMMATION MEDIATORS; MALE; RATS; RATS, WISTAR;

EID: 52449097135     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2008.00615.x     Document Type: Article

References (35)

1. Jankovic J. Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatry (2004) 75 951 957.
2. Aoki K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicol. (2005) 26 785 793.
3. Dressler D., Saberi F.A., Barbosa E.R. Botulinum toxin: mechanisms of action. Arq. Neuropsiquiatr. (2005) 63 180 185.
4. Troung D.D., Jost W.H. Botulinum toxin: clinical use. Parkinsonism Relat. Disord. (2006) 12 331 355.
5. Tsui J.K.C., Eisen A., Stoessl A., Calne S., Calne D.B. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet (1986) 2 245 247.
6. Wissel J., Kanovsky P., Ruzicka E. et al. Efficacy and safety of standardised 500 unit dose of Dysport (Clostridium botulinum toxin A haemaglutinin complex) in a heterogenous cervical dystonia population: results of prospective, multicentre, randomised, double-blind, placebo-controlled parallel group study. J. Neurol. (2001) 248 1073 1078.
7. Gobel H. Botulinum toxin in migraine prophylaxis. J. Neurol. (2004) 251 I8 I11.
8. Allam N., Brasil-Neto J.P., Broen G., Tomaz C. Injections of botulinum toxin type A produce pain alleviation in intractable trigeminal neuralgia. Clin. J. Pain (2005) 21 182 184.
9. Mahowald M.L., Singh J.A., Dykstra D. Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotox. Res. (2006) 9 179 188.
10. Jabbari B., Maher N., Difazio M.P. Botulinum toxin A improved burning pain and allodynia in two patients with spinal cord pathology. Pain Med. (2003) 4 206 210.
11. Cui M., Khanijou S., Rubino J., Aoki K.R. Subcutaneous administration of botulinum toxin type A reduces formalin-induced pain. Pain (2004) 107 125 133.
12. Bach-Rojecky L., Lackovic Z. Antinociceptive effect of botulinum toxin type A in rat model of the carrageenan and capsaicin induced pain. Croat. Med. J. (2005) 46 201 208.
13. Zimmermann M. Ethical guidelines for investigation of experimental pain in conscious animals. Pain (1983) 16 109 110.
14. Kontinen V.K., Aarnisalo A.A., Idänpään-Heikkilä J.J., Panula P., Kalso E. Neuropeptide FF in the rat spinal cord during carrageenan inflammation. Peptides (1997) 18 287 292.
15. Gilchrist H.D., Allard L.A., Simone D.A. Enhanced withdrawal responses to heat and mechanical following intraplantar injection of capsaicin in rats. Pain (1996) 67 179 188.
16. Winter C.A., Risley E.A., Nuss G.W. Carrageenin-induced oedema in hind paw of the rat as an assay for antiinflammatory drugs. Proc. Soc. Exp. Biol. Med. (1962) 111 544 547.
17. Udaka K., Takeuchi Y., Movat H.Z. Simple method for quantitation of enhanced vascular permeability. Proc. Soc. Exp. Biol. Med. (1970) 133 1384 1387.
18. Kawabata A., Kuroda R., Minami T., Kataoka K., Taneda M. Increased vascular permeability by a specific agonist of protease-activated receptor 2 in rat hindpaw. Brit. J. Pharmacol. (1998) 125 419 422.
19. Welch M.J., Purkiss J.R., Foster K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon (2000) 38 245 258.
20. Durham P.L., Cady R., Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by BoNTA: implications for migraine therapy. Headache (2004) 44 35 42.
21. Lam F.Y., Ferrell W.R. Inhibition of carrageenan-induced inflammation in the rat knee joint by substance P antagonist. Ann. Rheum. Dis. (1989) 48 928 935.
22. Helyes Z., Pozsgai G., Börzsei R. et al. Inhibitory effect og PACAP-38 on acute neurogenic and non-neurogenic inflammatory processes in the rat. Peptides (2007) 28 1847 1855.
23. Szolcsany J. Forty years in capsaicin research for sensory pharmacology and physiology. Neuropeptides (2004) 38 377 384.
24. Planells-Cases R., Garcia-Sanz N., Morenilla-Palao C., Ferrer-Montiel A. Functional aspects and mechanisms of TRPV1 involvement in neurogenic inflammation lead to thermal hyperalgesia. Pflugers Arch.- Eur. J. Physiol. (2005) 451 151 159.
25. Chuang Y.C., Yoshimura N., Wu M. et al. Intraprostatic capsaicin injection as a novel model for nonbacterial prostatitis and effects of botulinum toxin A. Eur. Urol. (2007) 51 1119 1127.
26. Doggweiler R., Zermann D.H., Ishigooka M., Schmidt R.A. Botox-induced prostatic involution. Prostate (1998) 37 44 50.
27. Maria G., Brisinda G., Civello I.M., Bentivoglio A.R., Sganga G., Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology (2003) 62 259 264.
28. Çayan S., Coşkun B., Bozlu M., Acar D., Akbay E., Ulcusoy E. Botulinum toxin type A may improve bladder function in a rat chemical cystitis model. Urol. Res. (2003) 30 399 404.
29. Gazerani P., Staahl C., Drewes A.M., Arendt-Nielsen L. The effect of botulinum toxin type A on capsaicin-evoked pain, flare and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain (2006) 122 315 325.
30. Tugnoli V., Capone J.G., Eleopra R. et al. Botulinum toxin type A reduces capsaicin-evoked and neurogenic vasodilatation in human skin. Pain (2006) 130 76 83.
31. Schulte-Mattler W.J., Opatz O., Blersch W., May A., Bigalke H., Wohlfahrt K. Botulinum toxin A does not alter capsaicin-induced pain perception in human skin. J. Neurol. Sci. (2007) 260 38 42.
32. Voller B., Sycha T., Gustorff B. et al. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology (2003) 61 940 944.
33. Sycha T., Samal D., Chizh B. et al. A lack of antinociceptive or anti-inflammatory effect of botulinum toxin A in an inflammatory human pain model. Anaesth. Analg. (2006) 102 509 516.
34. Comperat E., Reitz A., Delcourt A., Capron F., Denys P., Chartier-Kastler E. Histologic features in the urinary bladder wall affected from neurogenic overactivity-a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur. Urol. (2006) 50 1058 1064.
35. Luvisetto S., Marinelli S., Lucchetti F. et al. Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice. Brain Res. (2006) 1082 124 131.